COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD ZincZn
HC Q study #16
Source   PDF   Share   Tweet
See all 155 studies
4/21
Negative
Late treatment study
Magagnoli et al., Med (2020), doi:10.1016/j.medj.2020.06.001 (preprint 4/21) (Peer Reviewed)
Outcomes of hydroxych loroquine usage in United States veterans hospitalized with Covid-19
Retrospective 368 hospitalized patients, no statistically significant reduction in mortality or the need for mechanical ventilation with HC Q or HC Q+AZ, or for death with HC Q+AZ, HR 1.83, p=0.009 for HC Q mortality.
The preprint notes that HC Q was more likely to be prescribed to patients with more severe disease, however this was deleted in the published version.
425 patients had dispositions of death or discharge by the end of the study period and thus did not encounter the issue of length-biased sampling and differential rates of right-censored observations among the groups.
death, ↑31.0%, p=0.28
death, ↑83.0%, p=0.009
death, ↓11.0%, p=0.75, HCQ+AZ w/dispositions
death, ↓1.0%, p=0.98, HCQ w/dispositions
Source   PDF   Share   Tweet
See all 155 studies
Please send us corrections, updates, or comments.
Submit